ANDA Submission Consulting

Reduce ANDA submission timelines and operational costs while maintaining expert regulatory oversight.

Accelerate ANDA Development with Regulatory Expertise and AI-Driven Efficiency

Successful ANDA submissions require more than technical documentation; they require regulatory strategy, submission excellence, and a deep understanding of FDA expectations.

ProPharma combines regulatory expertise with an AI-enabled submission platform to help generic drug sponsors streamline ANDA preparation, reduce operational burden, and accelerate submission readiness without compromising quality or compliance.

From first-time filers to established generic manufacturers, we provide the strategic guidance, technical expertise, and scalable support needed to move confidently from development to approval.

The ProPharma Difference: Expertise Enhanced by Innovation

Successful ANDA submissions require more than speed. They demand regulatory expertise, scientific rigor, and a clear understanding of FDA expectations.

Our proprietary approach to generic drug development combines experienced regulatory professionals with a novel AI-driven approach designed to improve efficiency without compromising quality. Our technology helps streamline document development, enhance consistency, and reduce manual effort, while our experts provide the strategic guidance, scientific review, and regulatory oversight needed to support submission success.

This expert-led, AI-enabled model helps sponsors:

  • Accelerate submission timelines
  • Improve consistency and quality across application components
  • Reduce operational burden on internal teams
  • Scale submission activities more efficiently
  • Maintain confidence in regulatory compliance and submission readiness

Backed by former FDA professionals, CMC specialists, regulatory strategists, medical writers, and publishing experts, our team delivers the expertise and innovation needed to navigate ANDA submissions with greater speed.

Comprehensive ANDA Submission Support

From development planning through FDA review and approval, our team provides end-to-end support across the ANDA lifecycle.

Regulatory Strategy and Submission Planning

A successful ANDA begins with a clear regulatory strategy. Our experts help sponsors identify risks early, align development activities with FDA expectations, and establish an efficient path to submission.

Services include:

  • Regulatory pathway assessment
  • ANDA development strategy
  • FDA regulatory intelligence
  • Gap assessments and readiness evaluations
  • Submission planning and risk mitigation

ANDA Authoring, Publishing, & Submission Management

Our team supports the preparation, review, compilation, and publishing of high-quality ANDA submissions designed to facilitate efficient FDA review.

Services include:

  • Technical and scientific writing
  • Submission-ready document development
  • Content review and quality control
  • Submission compilation and management
  • eCTD publishing support

CMC and Bioequivalence Support

ProPharma provides integrated technical support across CMC and bioequivalence activities, helping sponsors develop, document, and present critical data required for ANDA success.

Services include:

  • CMC strategy and documentation
  • Drug substance and drug product support
  • Manufacturing and facility information
  • Bioequivalence strategy
  • Technical data review and regulatory assessment
  • Submission integration and quality review

FDA Review, Deficiency Response, & Lifecycle Management

Our support extends beyond submission. We help sponsors navigate FDA interactions, respond to agency requests, and manage post-submission activities through approval and beyond.

Services include:

  • FDA correspondence management
  • Information request responses
  • Deficiency response preparation
  • Complete Response Letter (CRL) remediation
  • Post-approval regulatory support
  • Lifecycle CMC and submission management

Supporting Generic Drug Sponsors Across the Product Lifecycle

Our team of expert regulatory consultants supports organizations at every stage of generic drug development, including:

  • Emerging pharmaceutical companies
  • Generic drug manufacturers
  • Specialty pharmaceutical organizations
  • Contract development and manufacturing organizations (CDMOs)
  • Global companies entering the US market

Whether you need support for a single submission or an ongoing regulatory partner, our team can scale to meet your needs.

Several business professionals having fun at a business meeting

Why Partner with ProPharma? 

Casually worker business professionals collaborating at a conference table

Successful ANDA submissions require the right combination of expertise, strategy, and execution.

Sponsors choose ProPharma because we offer:

  • Deep FDA and generic drug expertise
  • Former FDA professionals and industry leaders
  • Integrated regulatory, CMC, and submission capabilities
  • Proprietary AI-enabled efficiencies with expert oversight
  • Flexible support models tailored to your organization
  • End-to-end support from planning through approval

Our team helps sponsors reduce regulatory risk, improve operational efficiency, and accelerate the path to approval.

Ready to Accelerate Your ANDA Submission? 

Whether you are preparing your first ANDA or seeking a more efficient approach to managing submission volume, ProPharma can help. Connect with our Regulatory Sciences experts to discuss your program, timeline, and regulatory objectives.

ProPharma: The World's Leading Regulatory Consultancy

Contact us today to discuss your case and learn how our experts can strengthen your ANDA submission increasing efficiency and reducing the costs of application development.

News & Insights

Digital Transformation First: Why AI Investment Depends on Strategy, Data, and Operational Readiness

August 10, 2026

Digital Transformation First: Why AI Investment Depends on Strategy, Data, and O...

Discover why a solid digital transformation strategy is crucial before investing in AI, ensuring successful adoption and measurable impact in life sciences.

Is Your Clinical Trial at Risk: When to Consider a Rescue Strategy

August 6, 2026

Is Your Clinical Trial at Risk: When to Consider a Rescue Strategy

Identify the warning signs of a clinical trial at risk and learn when to implement a structured rescue strategy to ensure study success and data integrity.

Top 7 QMSR Readiness Gaps Medical Device Manufacturers Should Assess Before an FDA Inspection

August 5, 2026

Top 7 QMSR Readiness Gaps Medical Device Manufacturers Should Assess Before an F...

FDA's QMSR is now in effect. Learn the seven most common quality system gaps medical device manufacturers should assess to prepare for FDA inspections and achieve QMSR compliance.

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

July 8, 2026

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...

ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Achieving Continuous Audit Readiness Across a Global Medical Information Program - ProPharma

August 3, 2026

Achieving Continuous Audit Readiness Across a Global Medical Information Program

Maintaining continuous audit readiness across a global Medical Information operation requires more than periodic audit preparation. Organizations operating across multiple countries and affiliates...

Case Study Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation - ProPharma

July 23, 2026

Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation

As artificial intelligence becomes increasingly embedded across life sciences, organizations face a growing challenge: ensuring quality and compliance frameworks evolve alongside rapidly advancing...

Case Study Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A Regulatory and Pharmacovigilance-Led Solution - ProPharma

July 15, 2026

Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A...

Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...

From Feasibility to First Patient In: How to Streamline Study Start-Up  

September 30, 2026

From Feasibility to First Patient In: How to Streamline Study Start-Up  

Clinical trial delays often begin long before study conduct, with critical decisions made during feasibility and study start-up shaping the success of the entire trial. Join this webinar to discover...

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

June 4, 2026

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

News & Insights

Digital Transformation First: Why AI Investment Depends on Strategy, Data, and Operational Readiness

August 10, 2026

Digital Transformation First: Why AI Investment Depends on Strategy, Data, and O...

Discover why a solid digital transformation strategy is crucial before investing in AI, ensuring successful adoption and measurable impact in life sciences.

Is Your Clinical Trial at Risk: When to Consider a Rescue Strategy

August 6, 2026

Is Your Clinical Trial at Risk: When to Consider a Rescue Strategy

Identify the warning signs of a clinical trial at risk and learn when to implement a structured rescue strategy to ensure study success and data integrity.

Top 7 QMSR Readiness Gaps Medical Device Manufacturers Should Assess Before an FDA Inspection

August 5, 2026

Top 7 QMSR Readiness Gaps Medical Device Manufacturers Should Assess Before an F...

FDA's QMSR is now in effect. Learn the seven most common quality system gaps medical device manufacturers should assess to prepare for FDA inspections and achieve QMSR compliance.

Previous Post Arrow Next Post Arrow
ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

July 8, 2026

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...

ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Achieving Continuous Audit Readiness Across a Global Medical Information Program - ProPharma

August 3, 2026

Achieving Continuous Audit Readiness Across a Global Medical Information Program

Maintaining continuous audit readiness across a global Medical Information operation requires more than periodic audit preparation. Organizations operating across multiple countries and affiliates...

Case Study Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation - ProPharma

July 23, 2026

Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation

As artificial intelligence becomes increasingly embedded across life sciences, organizations face a growing challenge: ensuring quality and compliance frameworks evolve alongside rapidly advancing...

Case Study Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A Regulatory and Pharmacovigilance-Led Solution - ProPharma

July 15, 2026

Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A...

Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...

Previous Resource Arrow Next Resource Arrow
From Feasibility to First Patient In: How to Streamline Study Start-Up  

September 30, 2026

From Feasibility to First Patient In: How to Streamline Study Start-Up  

Clinical trial delays often begin long before study conduct, with critical decisions made during feasibility and study start-up shaping the success of the entire trial. Join this webinar to discover...

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

June 4, 2026

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Previous Webinar Arrow Next Webinar Arrow